Caplyta® (lumateperone) open-label safety switching study in patients with schizophrenia published in the journal, schizophrenia research

Patients with stable symptoms of schizophrenia were switched from previous antipsychotic medications with no dose titration to caplyta 42 mg for a 6-week treatment duration, then switched back to previous or another approved antipsychotic.
ITCI Ratings Summary
ITCI Quant Ranking